Innogen Pharmaceuticals Receives GMP Certification, Accelerating Global Expansion of Efsubaglutide Alfa

Innogen Pharmaceuticals (HK.2591) has achieved a significant milestone as its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a PIC/S GMP certification inspection. This internationally recognized quality standard is crucial for the broader availability of the company's drug on global markets.

The certification represents a critical step in the commercialization of Efsubaglutide alfa, a drug developed by Innogen for metabolic diseases. Quality control and the standardization of manufacturing processes are central to the biopharmaceutical company's growth strategy, particularly as it aims for international expansion.

Innogen Pharmaceuticals focuses on the discovery and industrialization of novel drugs for metabolic diseases. The approval of the Efsubaglutide alfa manufacturing process under international standards reinforces the company's capability to produce high-quality pharmaceuticals for worldwide distribution.

The company anticipates that this certification will significantly accelerate the market entry and enhance the global competitiveness of Efsubaglutide alfa.